Sheraz Azhar, Medical Oncology SpR at the University Hospitals of Leicester NHS Trust and Founder of OncsCare, shared a post on LinkedIn:
“Today in trials clinic, a patient on a HER2-altered lung cancer study asked me about what comes next. She mentioned Enhertu – something she’d been reading about through online patient communities. She wasn’t looking for guarantees. She wanted honesty, perspective, and to know that options are still being thought about.
That conversation stayed with me.
We often talk about clinical trials in terms of protocols and endpoints. For patients, they’re about continuity – knowing the road doesn’t end at progression. Many patients are incredibly well informed, and the HER2 lung cancer space is moving fast, even if unmet need remains. It’s also a reminder of why real-world data matters. Not just trial results, but how we test, treat, and support patients day to day – especially when they ask,
‘What happens if this stops working?’
Alongside this, we’re running a multicentre audit of HER2-altered lung cancer and would love to collaborate. Thank you to the centres who’ve already contributed – your data is genuinely appreciated. If your centre manages patients with HER2-mutant or HER2-expressing lung cancer and would like to be involved, please get in touch.”
More posts featuring Sheraz Azhar.